

| <i>Short Name</i>  | <i>Comments</i>   | <i>Type</i>           | <i>Investigator</i>                                   | <i>Contact</i>  |
|--|---|-----------------------|---|---|
| <b><i>Disease site specific</i></b>                        |   |                       |   |   |
| <b><i>Treatment</i></b>                                    |   |                       |   |   |
| CP-MGA271-03   | Macrogenics Protocol CP-MGA271-03: A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers | Treatment             | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| EA 3132  | Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck<br><a href="#">For More Information</a>  | Treatment             | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| Wake Forest<br>97115                                       | HEAD & NECK: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia<br><br><a href="#">For More Information</a>  | Symptom<br>Management | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
| <b><i>Protocols that are NOT disease site specific</i></b> |   |                       |   |   |
| <b><i>Treatment</i></b>                                    |   |                       |   |   |
| Alexion<br>ALXN6000-ONC-102                                | Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer  | Treatment             | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
|  | A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity  | Treatment             | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |

|                           |   |           |   |                                 |
|---------------------------|---|-----------|---|---------------------------------|
|                           | <b>A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin</b> | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
|                           | <b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas</b>   | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
|                           | <b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors</b>   | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>ALEXO<br/>AT148001</b> | <b>Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>ABBVIE M15-394</b>     | <b>Abbvie Protocol M15-394: A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor</b>   | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
|                           | <b>A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>SCI-CD47-001</b>       | <b>First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>MK-4280-001</b>        | <b>A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies</b>  | Treatment | <a href="#">START</a><br><a href="#">Midwest</a><br><a href="#">Investigators</a> | START Midwest<br>(616) 954-5554 |

|                             |   |           |   |                                 |
|-----------------------------|---|-----------|---|---------------------------------|
| <b>LZM009-001</b>           | <b>A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>ASN002</b>               | <b>A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>20150195<br/>AMG 820</b> | <b>A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>R3767-ONC-<br/>1613</b>  | <b>A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies</b> | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>CP-MGA012-01</b>         | <b>A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>MK-4820</b>              | <b>A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>ASN003-101</b>           | <b>A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |
| <b>BGB-290</b>              | <b>A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a> | START Midwest<br>(616) 954-5554 |

|                     |   |           |   |   |
|---------------------|---|-----------|---|---|
| <b>MK-8353-013</b>  | <b>A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>5F9004</b>       | <b>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>CP-MGA012-01</b> | <b>A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>CVM-001</b>      | <b>A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer</b>   | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>APX_CLN_0011</b> | <b>A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors</b>  | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>CPI-1205-202</b> | <b>A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors</b> | Treatment | <a href="#">START<br/>Midwest<br/>Investigators</a>   | START Midwest<br>(616) 954-5554   |
| <b>NRG CC003</b>    | <b>Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer</b>   | Treatment | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|                     | <a href="#">For More Information</a>  |           |   |   |
| <b>NRG CC001</b>    | <b>A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases</b>   | Treatment | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|                     | <a href="#">For More Information</a>  |           |   |   |

|                            |   |                        |   |  |
|----------------------------|---|------------------------|---|--|
| A071401                    | Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations<br><br><a href="#">For More Information</a>  | Treatment              | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| <b>Molecular Profiling</b> |   |                        |   |  |
| QOL Multisite<br>EAQ-152   | EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Aadvanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling<br><br><a href="#">For More Information</a> | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - MATCH             | MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below<br><br><a href="#">For More Information</a>  | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131                     | <i>Dasatinib</i> in Patients with Tumors with DDR2 Mutations<br><br><a href="#">For More Information</a>  | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - A                 | Solid Tumors (Other than SC & NSCLC) or Lymphomas; <i>Afatinib</i> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment<br><br><a href="#">For More Information</a>  | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - B                 | Tumors with HER2 Activating Mutations; Treatment: <i>Afatinib</i><br><br><a href="#">For More Information</a>   | Molecular<br>Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |

|             |  |                        |   |   |
|-------------|--|------------------------|---|---|
| EAY131 - C1 | <b><u>Crizotinib</u></b> in Patients with Tumors with MET Amplification  | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |
| EAY131 - C2 | <b><u>Crizotinib</u></b> in Patients with Tumors with MET Exon 14 Deletion   | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |
| EAY131 - E  | <b>Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u>AZD9291</u></b>                     | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |
| EAY131 - F  | <b>Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u>Crizotinib</u></b>                              | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |
| EAY131 - G  | <b>ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u>Crizotinib</u></b>  | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |
| EAY131 - H  | <b>Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u>Dabrafenib</u> and <u>Trametinib</u></b> | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |
| EAY131 - J  | <b><u>Trametinib</u> and <u>Pertuzumab</u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification</b>             | Molecular<br>Profiling | <a href="#">CRCWM<br/>Physician<br/>Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|             | <a href="#">For More Information</a>   |                        |   |   |

|             |   |                     |   |  |
|-------------|---|---------------------|---|--|
| EAY131 - L  | Phase II Study of MLN0128 ( <u>TAK-228</u> ) in Patients with Tumors with mTOR Mutations<br><br><a href="#">For More Information</a>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - M  | Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations<br><br><a href="#">For More Information</a>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - R  | BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u><br><br><a href="#">For More Information</a>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - S1 | <u>Trametinib</u> in Patients with Tumors with NF1 Mutations<br><br><a href="#">For More Information</a>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - S2 | <u>Trametinib</u> in Patients with Tumors with GNAQ or GNA 11 Mutations<br><br><a href="#">For More Information</a>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - T  | Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u>GDC-0449 (vismodegib)</u><br><br><a href="#">For More Information</a> | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |
| EAY131 - V  | Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u>Sunitinib</u><br><br><a href="#">For More Information</a>        | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="#">www.crcwm.org</a> |

|              |  |                     |   |   |
|--------------|--|---------------------|---|---|
| EAY131 - W   | <b>Phase II Study of <u>AZD4547</u> in Patients with Tumors with Aberrations in the FGFR Pathway</b>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - X   | <b><u>Dasatinib</u> in Patients with Tumors with DDR2 Mutations</b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - Y   | <b><u>AZD5363</u> in Patients with Tumors with AKT Mutations</b>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - Z1A | <b><u>Binimetinib</u> in Patients with Tumors (Other than Melanoma) with NRAS Mutations</b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - Z1B | <b>MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC</b> | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - Z1D | <b><u>Nivolumab</u> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)</b>  | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |
| EAY131 - Z1E | <b>Testing <u>LOXO-101</u> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes</b>  |                     | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|              | <a href="#">For More Information</a>   |                     |   |   |



|                              |  |                     |   |   |
|------------------------------|--|---------------------|---|---|
| EAY131 - Z1I                 | Testing <u>AZD1775</u> as a Possible Treatment in People who have Cancer with BRCA Mutations   |                     | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                              | <a href="#">For More Information</a>   |                     |   |   |
| ASCO TAPUR                   | Targeted Agent and Profiling Utilization Registry Study. <u>All Drugs Provided</u>   | Molecular Profiling | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                              | <a href="#">For More Information</a>   |                     |   |   |
| <b>Biorepository</b>         |  |                     |   |   |
| NCI PDM 9846                 | Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)   | Biobanking          | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                              | <a href="#">For More Information</a>   |                     |   |   |
| SHARE                        | The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators   | Biobanking          | Cottingham, Sandra                            | Spectrum Health Biorepository<br><a href="mailto:david.chesla@spectrumhealth.org">david.chesla@spectrumhealth.org</a><br>(616) 267-2629 |
|                              | <i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i> |                     |   |   |
| <b>Assessment/ Education</b> |  |                     |   |   |
| URCC 13059<br>GAP-70         | Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults   | Other               | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a>   |
|                              | <a href="#">For More Information</a>   |                     |   |   |

---

**Symptom Management**


---

|                |  |                    |   |   |
|----------------|--|--------------------|---|---|
| <b>S1415CD</b> | <b>A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)</b> | Symptom Management | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|----------------|--|--------------------|---|---|

[For More Information](#)

---

|                             |   |                    |   |   |
|-----------------------------|---|--------------------|---|---|
| <b>URCC 04040<br/>YOCAS</b> | <b>A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors</b> | Symptom Management | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|-----------------------------|---|--------------------|---|---|

[For More Information](#)

---

|                   |                                       |                    |   |   |
|-------------------|---------------------------------------|--------------------|---|---|
| <b>URCC 16070</b> | <b>Treatment of Refractory Nausea</b> | Symptom Management | <a href="#">CRCWM Physician Investigators</a> | CRCWM<br>(616) 391-1230<br><a href="http://www.crcwm.org">www.crcwm.org</a> |
|-------------------|---------------------------------------|--------------------|---|---|

[For More Information](#)